PATENT CLAIM ANALYSIS

Application Number: 15748284
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["424", "133100"]

Abstract:
The novel synergistic combination of immune checkpoint blockade and hematopoietic stem cell transplantation and/or hematopoietic stem cell mobilization yield synergistic effects in disease therapy.

Claim (Index 3):
The method of any one of  claims 1 - 2 , wherein the one or more immune checkpoint inhibitors are each an antagonist of programmed death 1 (PD-1), programmed death ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), V-domain Ig suppressor of T cell activation (VISTA), programmed death ligand 2 (PD-L2), indoleamine 2,3-dioxygenase (IDO), arginase, B7 family inhibitory ligand B7-H3, B7 family inhibitory ligand B7-H4, lymphocyte activation gene 3 (LAG3), 2B4, B and T lymphocyte attenuator (BTLA), T cell membrane protein 3 (TIM3; also known as HAVcr2), adenosine A2a receptor (A2aR), a killer inhibitory receptor, and/or signal transducer and activator of transcription (STAT)3.

Metadata:
- Claim Count in Document: 71.0
- Percentile: 86.0
- Lexical Diversity: 1.19048
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14021353', '15170284', '14158531', '16068816', '15024396']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7467547186798061
- 35 USC 102 Novelty (BERT): 0.5397417636641229
- Combined Prediction Score: 0.7260534231782378
- Mean Citation Score: 364.48628
- Max Citation Score: 390.14835
- Similarity Product: 273.36654817317725

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test